Patrick John Finn - 02 Dec 2021 Form 4 Insider Report for Twist Bioscience Corp (TWST)

Role
Chief Commercial Officer
Signature
/s/ William Solis, as Attorney-in-Fact for Patrick John Finn
Issuer symbol
TWST
Transactions as of
02 Dec 2021
Net transactions value
-$108,709
Form type
4
Filing time
06 Dec 2021, 15:35:08 UTC
Previous filing
23 Nov 2021
Next filing
23 Dec 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TWST Common Stock Options Exercise $40,443 +1,517 +4% $26.66 39,751 02 Dec 2021 Direct
transaction TWST Common Stock Options Exercise $5,623 +241 +0.61% $23.33 39,992 02 Dec 2021 Direct
transaction TWST Common Stock Sale $102,034 -1,172 -2.9% $87.06 38,820 02 Dec 2021 Direct F1
transaction TWST Common Stock Sale $52,740 -586 -1.5% $90.00 38,234 02 Dec 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TWST Employee Stock Option (right to buy) Options Exercise $0 -1,517 -4.2% $0.000000 34,891 02 Dec 2021 Common Stock 1,517 $26.66 Direct F2
transaction TWST Employee Stock Option (right to buy) Options Exercise $0 -241 -1.2% $0.000000 20,204 02 Dec 2021 Common Stock 241 $23.33 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on September 3, 2020.
F2 20% of the shares subject to the option vested and became exercisable on October 31, 2019, and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.
F3 25% of the shares subject to the option vested and became exercisable on October 24, 2020, and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date.